Treats skin and skin structure infections caused by Escherichia coli, Klebsiella…. ANDA 76794, held by Watson Laboratories. Ciprofloxacin Hydrochloride.
As of Nov 21, 2026, ANDA 76794 (Ciprofloxacin Hydrochloride), held by Watson Laboratories, was first approved by FDA on Jun 9, 2004, with 21 approved supplements and 0 published complete response letters.
Ciprofloxacin tablets are a fluoroquinolone antibacterial indicated in adults (18 years of age and older) with the following infections caused by designated, susceptible bacteria and in pediatric patients where indicated: Skin and Skin Structure Infections Bone and Joint Infections Complicated Intra-Abdominal Infections Infectious Diarrhea Typhoid Fever (Enteric Fever) Uncomplicated Cervical and Urethral Gonorrhea Inhalational Anthrax post-exposure in adult and pediatric patients Plague in adult and pediatric patients Chronic Bacterial Prostatitis Lower Respiratory Tract Infections ○ Acute Exacerbation of Chronic Bronchitis Urinary Tract Infections ○ Urinary Tract Infections (UTI) ○ Acute Un…
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 9, 2004 | Original application | Approved | None posted |
| Ciprofloxacin HydrochlorideEQ 250MG BASE · tablet;oral | Ciprofloxacin Hydrochloride | Rx |
| Ciprofloxacin HydrochlorideEQ 500MG BASE · tablet;oral | Ciprofloxacin Hydrochloride | Rx |
| Ciprofloxacin HydrochlorideEQ 750MG BASE · tablet;oral | Ciprofloxacin Hydrochloride | Rx |
| Jul 22, 2026 | Supplement 47Labeling · Standard review | Approved | None posted |
| Dec 19, 2022 | Supplement 46Labeling · Standard review | Approved | None posted |
| Dec 19, 2022 | Supplement 44Labeling · Standard review | Approved | None posted |
| Dec 19, 2022 | Supplement 43Labeling · Standard review | Approved | None posted |
| Dec 19, 2022 | Supplement 42Labeling · Standard review | Approved | None posted |
| Dec 19, 2022 | Supplement 40Labeling · Standard review | Approved | None posted |
| Dec 19, 2022 | Supplement 39Labeling · Standard review | Approved | None posted |
| Dec 19, 2022 | Supplement 38Labeling · Standard review | Approved | None posted |
| Dec 19, 2022 | Supplement 36Labeling · Standard review | Approved | None posted |
| Nov 10, 2015 | Supplement 34Labeling · Standard review | Approved | None posted |
| Nov 10, 2015 | Supplement 31Labeling · Standard review | Approved | None posted |
| Apr 25, 2013 | Supplement 29Labeling · Standard review | Approved | None posted |
| Mar 13, 2012 | Supplement 26Labeling | Approved | None posted |
| May 16, 2011 | Supplement 24Labeling | Approved | None posted |
| Aug 24, 2009 | Supplement 16Labeling | Approved | None posted |
| Dec 19, 2008 | Supplement 13Labeling | Approved | None posted |
| May 13, 2008 | Supplement 9Labeling | Approved | None posted |
| Feb 21, 2007 | Supplement 6Labeling | Approved | None posted |
| Oct 22, 2006 | Supplement 5Labeling | Approved | None posted |
| Aug 30, 2005 | Supplement 3Labeling | Approved | None posted |
| Feb 10, 2005 | Supplement 1Labeling | Approved | None posted |
| Jun 9, 2004 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters